New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Ribi ImmunoChem Research Inc.
Division of GlaxoSmithKline PLC
Latest From Ribi ImmunoChem Research Inc.
Vaccines Enter the New Age of Adjuvants
The US vaccine industry is a year away from a wave of new, more effective and longer-lasting adjuvant-enhanced products. The technology promises added protection to patients-and extra proprietary rights to product marketers.
Living with Limits: Device and Biotech Venture Capital
Lacking exits from either IPOs or acquisitions, squeezing returns out of biotech and device start-ups has become an increasingly difficult game. Many generalist VC firms have fled to the far more lucrative business of Internet and IT investing, particularly since both health care and IT have become far more technologically complex. Thus specialists have been taking over a much greater percentage of health care dealmaking, though shunning most of the high-risk biotech and device investing of the 80s and 90s. Their investments begin with a clearly defined, and sometimes pre-arranged, exit.
Biotech Consolidation: Even News is No News
The only thing more noteworthy about the recent biotech M&A is than its volume is the silence that surrounds it: from Wall Street, the press, and Big Pharma. The problem is the consolidations themselves: largely intra-biotech affairs. Unless Big Pharma gets involved--and they've shown no interest in doing so--investors aren't going to get paid in what they want most out of an acquisition: liquid currency.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
-
Robert E Ivy, Chmn., Pres. & CEO
Vern D Child, VP, Fin. & Treas.
Charles Richardson, PhD, VP, Pharmaceutical Discovery
John L Cantrell, PhD, EVP
Gary T Elliott, PhD, VP, Pharmaceutical Dev.
Gary T Von Eschen, PhD, VP, Clinical & Regulatory Affairs - Contact Info
-
Ribi ImmunoChem Research Inc.
Phone: (406) 363-6214
553 Old Corvallis Rd.
Hamilton, MT 59840-3131
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ribi ImmunoChem Research Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice